AQR Arbitrage’s Inovio Pharmaceuticals INO Stock Holding History

AQR Arbitrage’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,752	Closed	-$156K	–	546
2020 Q1	$156K	Buy	+1,752	New	+$108K	0.01%	485

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

AQR Arbitrage's INO Position: Q2 2020 in Review

AQR Arbitrage sold out of Inovio Pharmaceuticals (INO) in Q2 2020, closing a stake of 1,752 shares — an estimated $156K sold.

AQR Arbitrage first reported a position in INO in Q1 2020 and held it in 1 quarter. The position peaked at $156K in Q1 2020. 214 funds tracked by Wall St. Rank hold INO as of Q2 2020.

AQR Arbitrage reported no remaining Inovio Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
AQR Arbitrage sold 1,752 Inovio Pharmaceuticals shares in Q2 2020, an estimated $156K.
AQR Arbitrage first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 1 quarter.
AQR Arbitrage's Inovio Pharmaceuticals position peaked at $156K in Q1 2020.
214 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2020.

Based on AQR Arbitrage's 13F filing for Q2 2020, filed 17 Aug 2020.